Last reviewed · How we verify

Psoriasis — Treatment Landscape & Competitive Intelligence

Psoriasis (Dermatology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Dermatology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Skyrizi RISANKIZUMAB AbbVie Interleukin-23 Antagonist [EPC] Interleukin-23 subunit alpha 2019-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortifoam HYDROCORTISONE ACETATE Pfizer Corticosteroid Corticosteroid-binding globulin 1951-01-01
Stelara Stelara Biocon Biologics UK Ltd Interleukin-12, Interleukin-23

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 10 drugs in Psoriasis
  2. Pfizer · 4 drugs in Psoriasis
  3. Generic (originally Schering) · 2 drugs in Psoriasis
  4. Biocad · 1 drug in Psoriasis
  5. Biocon Biologics UK Ltd · 1 drug in Psoriasis
  6. Generic (originally Lederle Laboratories) · 1 drug in Psoriasis
  7. Generic (originally Merck) · 1 drug in Psoriasis
  8. Generic (originally Merck/Upjohn) · 1 drug in Psoriasis
  9. AbbVie · 1 drug in Psoriasis
  10. Generic (originally Upjohn/Pfizer) · 1 drug in Psoriasis
  11. Hannover Medical School · 1 drug in Psoriasis
  12. Johnson & Johnson · 1 drug in Psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Psoriasis:

Cite this brief

Drug Landscape (2026). Psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psoriasis. Accessed 2026-05-13.

Related